trial
as of 2026-07-01Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
NCTId NCT00742079
at a glance
Phase 4 · Completed
Enrollment 21 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2010-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
21 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2006-09
Primary completion
2010-07
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Massachusetts General HospitalLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
Investigators
1
Donald C. Goff, MDPrincipal Investigator
Sites
1 total
Boston, United States
Facts & assertions
4 sourced
Enrollment
21
Phase
PHASE4
Primary Completion Date
2010-07
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
collaborator
indication
investigator
person